Author

Nishu Gaind

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Clinical and economic benefits of bivalent Respiratory syncytial virus prefusion F (RSVpreF) vaccine for prevention of RSV in adults: a cost-effectiveness analysis for Singapore.

BACKGROUND Respiratory syncytial virus (RSV) is a common virus causing severe illness in adults. RSV prefusion F protein subunit (RSVpreF) vaccine was approved by the Singapore Health Sciences Authority for adults aged 18-59 years at increased risk and for adults aged ≥ 60 years, to prevent RSV-associated lower respira...

K. Thakkar, A. Shajarizadeh, Nishu Gaind et al. · Expert review of pharmacoeco... · 0 citations

Open access Sep 2026

Clinical and economic impact of bivalent respiratory syncytial virus prefusion F (RSVpreF) vaccination in older adults: a cost-effectiveness analysis for Chile.

BACKGROUND Respiratory syncytial virus (RSV) is a major cause of lower respiratory tract disease in older adults in Chile. Chile's National Immunization Technical Advisory Group (NITAG) recommended RSV vaccination for adults aged ≥60 years with risk factors for severe illness. This study estimated the cost-effectivenes...

Rafael Bolaños, Tomas Eduardo Abbott, A. Shajarizadeh et al. · Expert Review of Vaccines · 0 citations

Open access Aug 2026

Cost-Effectiveness Analysis of Older Adult Vaccination with the Bivalent Respiratory Syncytial Virus Prefusion F (RSVpreF) Vaccine in Mexico

Year-round RSVpreF vaccination in Mexico among adults aged 60–99 years could substantially reduce medically attended RSV cases and RSV-related mortality and is projected to be cost-effective, thereby supporting the adoption of preventive strategies to address the growing clinical and economic burden of RSV in Mexico’s...

V. Guajardo, A. Shajarizadeh, Nishu Gaind et al. · Vaccines · 0 citations